CJC-1295 with GHRP-6
CJC-1295 (no DAC) with GHRP-6
Written by Aaron CuhaReviewed Sep 2026
Also known as: CJC/GHRP-6, Mod GRF 1-29 with GHRP-6
In plain English, from Aaron
This is how I would explain it to a friend. The evidence, with the numbers, is further down the page.
Same idea as the last one with the hungriest peptide of the family in the second slot. GHRP-6 is the original growth hormone hexapeptide. People who want to eat pick it on purpose. People who do not want to eat find out the hard way. No one has tested this vial.
What people take it for
- Better sleep.
- Eating more, on purpose, when gaining weight is the goal.
- Losing fat and holding muscle.
- Healing faster.
What the trials actually showed
Nobody has tested the pair. GHRP-6 does have real human numbers. Nine healthy men got it by drip. It spread through the body in about 7.6 minutes and cleared with a half life of about 2.5 hours. Four of the nine had odd spikes on the way out. The other half of the vial is a puzzle. If it holds the long acting GHRH molecule, its half life is 5.8 to 8.1 days. If it holds the short one most no DAC vials contain, it is gone in minutes. Either way the two halves do not match. One lasts a hundred times longer than the other, or both are gone in hours. For the drug classes together, a 24 hour drip of a GHRP with GHRH beat GHRH alone in healthy older adults. That used the other GHRP, in a clinic. Sellers do not agree on vial sizes, so this page will not give you a per unit number.
What people report
Reports, not trial results
The good
- Deep sleep in the first weeks.
- Hunger, if hunger is what you want.
The bad
- Hunger that hits within minutes and is hard to ignore. That is the receptor doing its job, not a bad batch.
- A hot flushed face after the shot.
- Water retention and tingling hands at bigger draws.
- Most people quit it for ipamorelin, and the appetite is why.
- You cannot turn the hunger down on its own.
Where these come from: Peptide and gym forums, clinic write-ups and seller pages. The appetite effect is backed by controlled human work on this drug class.
My bottom line
If you are trying to lose fat, this is the wrong vial. The hunger is the point of the molecule, not a side effect you can dial out.
An opinion, not a finding. I am a coach, not a doctor.
Overview
The same two-receptor pairing as the GHRP-2 version with the hungriest secretagogue of the group in the second slot. GHRP-6 has published human pharmacokinetics in nine male volunteers, with an elimination half-life of about 2.5 hours, against a GHRH half that either lasts days or minutes depending on which molecule is actually in the vial. Nobody has studied the blend.
GHRP-6 is the original growth hormone releasing hexapeptide and the one with the strongest appetite effect in the family. That is why it persists in this market: people who want to eat choose it deliberately, and people who do not want to eat find out about it the hard way.
The human pharmacokinetics exist and are worth knowing. A single intravenous bolus in nine healthy male volunteers gave a distribution half-life of about 7.6 minutes and an elimination half-life of about 2.5 hours, with a bi-exponential disposition and area under the curve rising roughly in proportion to dose. That is a real measurement in real people and it is also the entirety of the human pharmacokinetic file for this component.
Set that next to the other half. If the vial contains genuine CJC-1295 with drug affinity complex, its half-life is 5.8 to 8.1 days. If it contains the mod GRF 1-29 that most no-DAC vials hold, it clears in minutes. Either way the two halves are mismatched: either one component lasts a hundred times longer than the other, or both are gone within hours and the vial is a short pulse of both. A single fixed ratio cannot be right for both cases, and the buyer usually cannot tell which case they are in.
On the arithmetic, vendors sell this at several splits and no size is canonical across the market, so this page does not print a per-unit figure. What is fixed regardless of split is that the plunger moves both, so the appetite effect and the GHRH effect rise and fall together.
Mechanism of action
GHRP-6 is a hexapeptide agonist at the growth hormone secretagogue receptor, the ghrelin receptor, which triggers a growth hormone pulse and also drives appetite, and at higher exposures raises cortisol and prolactin more than the newer selective agents. The GHRH analogue raises pulse amplitude at a separate receptor. The mechanistic case for combining them is the same two-receptor logic tested for the class with infusions, not with this vial.
Human evidence
The pair has never been studied. Each half has human pharmacology and neither has an outcome trial.
- The blend: no published study, no registered trial.
- GHRP-6: single-dose intravenous pharmacokinetics in nine healthy men, elimination half-life about 2.5 hours. No efficacy trial for any of the reasons people buy it.
- GHRH analogue half: the published human study covers the long-acting drug affinity complex form, not the material typically sold.
- Class combination: GHRP plus GHRH by infusion beat GHRH alone on growth hormone output in healthy older adults.
What this does not tell you: Growth hormone and IGF-1 are the endpoints in all of this. No trial in this class has measured muscle, fat, recovery or function in the people who buy it, over the durations they run it.
What it has been measured to do
Measured in people
Goals CJC-1295 with GHRP-6 has been measured for in a human being, most people first. Counts come from the study lines on this page and deliberately undercount.
- Growth hormone and IGF-1no headcount stated · 1 study
What people using it report
Uncontrolled and self-selected, so it cannot show that anything works. It is still the best guide on this page to what people actually do with CJC-1295 with GHRP-6, what they expect, and what goes wrong. The full account, including the negative reports, is below.
34 of the 36 indexed goals have no study of any kind behind CJC-1295 with GHRP-6
No trial, no animal work, no cell work on this page reports a result for these. That is an absence of evidence rather than evidence of absence, but it does mean anything you have been told about CJC-1295 with GHRP-6 and one of these did not come from a study cited here.
Reading the research record
GHRP-6's appetite effect is the reason this version still sells and also the reason most people leave it. It is not a side effect in the incidental sense; it is a direct consequence of agonism at the ghrelin receptor, the same receptor that makes you hungry before dinner. A fixed blend means the only way to reduce it is to reduce the GHRH half at the same time.
The older GHRPs also raise cortisol and prolactin more than ipamorelin does, which is the single reason ipamorelin displaced them in this market. That is a relative statement from pharmacology rather than from a head to head trial of blends, and no such trial exists.
The evidence, charted
Fig. 1a · evidence scale
9people, across 1 human study cited here
- 2013 · European Journal of Pharmaceutical Sciences9100%
The whole total is one study of 9. Counts are the enrollment each human citation on this page states, which includes observational cohorts where nobody was given the compound. 2 further human citations state no participant count and are not counted here. Studies still recruiting are excluded, and only studies cited on this page are counted.
Fig. 1b · evidence mix
3 of 4 citations here are human work, the rest is not.
- Human · given to people375%
- Review · summarises other work125%
Counted from the citation list on this page, typed as this page types it. It understates any literature larger than the sources we cite, and a review counts once however many studies it covers.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2004 to 2018, counted from the citation list on this page. The newest citation on file is from 2018, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Not approved
UK
Not approved
AU
Not approved
CA
Not approved
Not approved in any of the four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Fig. 5 · molecular identity
- Modality
- Blend
- Molecular weight
- A mixture. GHRP-6 is about 873 Da.
- Half-life
- Stated in words, not a number
- Sequence length
- None on file
see the exact wording below
Half-life as stated on file: Not defined for the blend. The published figure for the ghrelin-receptor half is in the overview above, and the mixture itself has never been measured.
No amino acid sequence is on file for CJC-1295 with GHRP-6, which is expected: a blend is not built from residues.
Fig. 6 · what is in the vial
No mass split can be drawn for this blend
Sellers do not publish a consistent vial size for CJC-1295 with GHRP-6, so the share of each component is not knowable from the outside. Splitting the bar evenly would invent the number this page exists to question.
- CJC-1295 (no DAC)amount not stated
- GHRP-6amount not stated
Component list from the product labels we hold. Amounts are label mass, never a dose.
Key studies & citations
- Human2013
Pharmacokinetic study of Growth Hormone-Releasing Peptide 6 (GHRP-6) in nine male healthy volunteers
Nine healthy men received single intravenous boluses of 100, 200 and 400 micrograms per kilogram. Averaged across doses the distribution half-life was 7.6 plus or minus 1.9 minutes and the elimination half-life 2.5 plus or minus 1.1 hours, with bi-exponential disposition and area under the curve increasing roughly in proportion to dose. Atypical concentration spikes appeared during the elimination phase in four of the nine subjects.
European Journal of Pharmaceutical Sciences - Human2006
Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults
Single subcutaneous injections of CJC-1295 with drug affinity complex raised mean plasma growth hormone two to ten-fold for six days or more and IGF-1 1.5 to three-fold for nine to eleven days in healthy adults, with an estimated half-life of 5.8 to 8.1 days. The material usually sold as CJC-1295 without DAC is a different, short-acting molecule.
Journal of Clinical Endocrinology and Metabolism - Human2004
Sustained elevation of pulsatile growth hormone (GH) secretion and insulin-like growth factor I (IGF-I), IGF-binding protein-3 (IGFBP-3), and IGFBP-5 concentrations during 30-day continuous subcutaneous infusion of GH-releasing peptide-2 in older men and women
Combining a ghrelin-receptor agonist with GHRH over 24 hours drove growth hormone secretion beyond either agent alone in healthy older adults. This is the closest thing to combination evidence for the class, and it used GHRP-2 rather than GHRP-6, by infusion rather than by injection from a blended vial.
Journal of Clinical Endocrinology and Metabolism - Review2018
The Safety and Efficacy of Growth Hormone Secretagogues
A review of the secretagogue class, covering the differing cortisol, prolactin and appetite profiles across GHRPs and the distance between the endocrine effects that are measured and the clinical claims that are made.
Sexual Medicine Reviews
What users report
Self-reported experiences, not evidence. Nothing below was measured under controlled conditions, and reports like these cannot separate a real effect from placebo, from the training or diet change that accompanied it, or from what the product actually contained. They are here because knowing what people describe, including what goes wrong, is worth reading alongside the studies.
- Hunger that arrives within minutes of injecting and is described as difficult to ignore.
- Deep sleep in the first weeks.
- Flushing and a warm face shortly after the shot.
- Water retention and tingling in the hands at higher amounts.
- People abandoning it for ipamorelin specifically because of the appetite.
Sources: Peptide and bodybuilding forums, clinic write-ups and vendor pages. Uncontrolled reports. The appetite effect is the one item here that is also supported by controlled human work on this drug class.
Frequently asked questions
How long does GHRP-6 last?
In nine healthy men given an intravenous bolus, the elimination half-life was about 2.5 hours with a distribution half-life of around seven and a half minutes.
Why does it make me so hungry?
It is an agonist at the ghrelin receptor, the receptor that signals hunger. That is the mechanism, not an impurity or a batch problem.
Is the combination studied?
Not this one. A GHRP with GHRH by infusion has been shown to raise growth hormone beyond GHRH alone in healthy older adults, using GHRP-2 in a research setting.
What vial size should I expect?
There is no canonical size. Vendors sell several splits, which is why this page does not print a per-unit figure. Work it from the milligram breakdown on your own label.
Is GHRP-6 or GHRP-2 the better half?
Neither has an outcome trial. GHRP-6 has the larger appetite effect, GHRP-2 has more human pharmacology behind it including a 30 day infusion study. Choose on side effects, because efficacy data to choose on does not exist.